The nationwide recall of a DMAA-containing pre-workout supplement raises renewed questions about stimulant pharmacology, cardiovascular safety, ingredient testing, and federal regulation of performance-enhancing supplements.

FDA Announces Nationwide Recall

The U.S. Food and Drug Administration (FDA) has announced a nationwide recall of RAPTURE Preworkout, manufactured by Leader Formulas, LLC, of Tomball, Texas, after laboratory testing identified the presence of 1,3-dimethylamylamine (DMAA), a synthetic stimulant with a controversial history in the sports nutrition industry.

The voluntary recall was announced on October 6, 2026, and published by the FDA on October 7. It involves one production lot of RAPTURE Preworkout distributed throughout the United States between January 29, 2025, and May 25, 2026.

The affected products were sold through retail outlets and online distribution channels. The recalled lot, identified as 260327-4, includes three flavors: Rainbow Twist, Electric Lemonade, and Berry Mojito.

According to the manufacturer’s recall announcement, no adverse events associated with the affected products had been reported at the time of publication. Nevertheless, the FDA considers DMAA an unsafe food additive and has repeatedly taken enforcement action against dietary supplements containing the substance.

What Is DMAA?

DMAA, chemically identified as 1,3-dimethylamylamine and also known as methylhexanamine, is an organic amine with the molecular formula C₇H₁₇N and a molecular weight of approximately 115.22 g/mol.

Historically, DMAA was used in pharmaceutical preparations, including nasal decongestants, before gaining popularity as an ingredient in thermogenic supplements, weight-management products, and pre-workout formulations.

Its commercial appeal stemmed primarily from its stimulant properties, which were marketed as supporting increased energy, mental alertness, exercise intensity, and physical performance.

DMAA became particularly prominent in the sports nutrition market during the late 2000s and early 2010s, when high-stimulant pre-workout formulations experienced substantial growth.

However, its popularity exceeded the available scientific evidence supporting its long-term safety or effectiveness as an ergogenic aid.

Pharmacological Mechanisms of DMAA

DMAA is commonly characterized as a sympathomimetic stimulant because its physiological effects resemble certain responses produced by activation of the sympathetic nervous system.

The sympathetic nervous system regulates several critical functions, including cardiovascular activity, vascular tone, and physiological responses to stress.

DMAA appears capable of influencing cardiovascular regulation through mechanisms associated with adrenergic signaling, although its precise molecular targets and pharmacodynamic characteristics in humans remain incompletely established.

Potential physiological effects include increased peripheral vascular resistance, elevated arterial blood pressure, and changes in cardiac workload.

Unlike caffeine, whose primary stimulant mechanism involves antagonism of adenosine receptors, DMAA’s pharmacology has not been characterized to the same degree in controlled human investigations.

This distinction is important because stimulant compounds can produce superficially similar subjective effects while differing substantially in their receptor interactions, cardiovascular consequences, and toxicological profiles.

The available evidence does not support treating DMAA as pharmacologically interchangeable with caffeine or classical amphetamine stimulants.

Cardiovascular Risks and Toxicological Concerns

The principal safety concerns associated with DMAA involve its potential effects on the cardiovascular system.

Increased peripheral vascular resistance can elevate blood pressure and increase the workload placed on the heart. Under certain physiological conditions, these changes may contribute to an imbalance between myocardial oxygen demand and oxygen delivery.

Individuals with hypertension, coronary artery disease, cardiac arrhythmias, or other cardiovascular abnormalities may be particularly susceptible to adverse effects from sympathomimetic stimulation.

The FDA has identified several potentially serious complications associated with DMAA exposure, including elevated blood pressure, chest tightness, shortness of breath, and myocardial infarction.

Importantly, the scientific literature does not establish that every individual exposed to DMAA will experience these complications. Severe adverse outcomes are influenced by numerous variables, including dose, concurrent substance use, underlying medical conditions, and individual physiological susceptibility.

Furthermore, case reports and adverse-event surveillance can identify potential safety signals but cannot always establish a direct causal relationship between a particular compound and an observed clinical event.

Nevertheless, the absence of comprehensive long-term safety data represents a significant limitation when evaluating DMAA for routine consumption in sports nutrition products.

DMAA and Caffeine: Potential for Combined Stimulant Effects

One of the more important considerations in pre-workout supplement formulation is the potential interaction between multiple stimulants.

Caffeine is widely incorporated into sports nutrition products because of its documented effects on alertness, perceived exertion, and certain measures of exercise performance.

Its primary mechanism involves competitive antagonism of adenosine receptors within the central nervous system.

DMAA, by contrast, produces stimulant effects through mechanisms that remain less clearly defined.

When consumed together, these compounds may produce additive or otherwise intensified cardiovascular responses, particularly with respect to blood pressure and sympathetic activation.

Although controlled human studies evaluating this combination are limited, the possibility of enhanced cardiovascular stress provides a pharmacological rationale for caution.

This concern becomes especially relevant when products contain multiple stimulant ingredients, proprietary blends, or undeclared pharmacologically active substances.

Does DMAA Improve Athletic Performance?

The presence of stimulant activity does not automatically establish meaningful ergogenic benefits.

An ergogenic substance must demonstrate measurable improvements in physical performance under controlled experimental conditions.

Although DMAA has historically been marketed for increased energy, concentration, and workout intensity, the available clinical evidence is insufficient to establish consistent improvements in muscular strength, hypertrophy, endurance capacity, or long-term training adaptations.

Subjective sensations such as increased stimulation, motivation, or perceived energy should not be confused with objectively measured improvements in athletic performance.

This distinction is particularly important in resistance training, where acute psychological stimulation may influence workout perception without necessarily producing superior muscular adaptations over time.

Consequently, the risk-benefit profile of DMAA remains difficult to justify based on the existing evidence.

FDA Regulation and the History of DMAA in Dietary Supplements

DMAA has been the subject of extensive regulatory controversy in the United States.

Under the Dietary Supplement Health and Education Act of 1994 (DSHEA), dietary supplement manufacturers are responsible for ensuring that their products comply with applicable federal requirements.

The FDA has maintained that DMAA does not qualify as a lawful dietary ingredient and considers its use in dietary supplements unlawful.

The agency has also challenged claims that DMAA is naturally derived from geranium plants, citing insufficient reliable scientific evidence supporting its occurrence as a natural botanical constituent.

Over the past decade, the FDA has pursued multiple enforcement actions involving DMAA-containing products, including warning letters, seizures, and other regulatory measures.

These actions reflect both concerns regarding the compound’s safety and the legal requirements governing substances marketed as dietary supplement ingredients.

Analytical Testing and Supplement Quality Control

The detection of DMAA in a commercially distributed pre-workout product highlights the importance of analytical testing and ingredient verification.

Modern analytical techniques, including high-performance liquid chromatography (HPLC) and liquid chromatography coupled with mass spectrometry (LC-MS), can be used to identify and quantify pharmacologically active compounds in complex supplement formulations.

These methods are particularly valuable when evaluating products containing multiple botanical extracts, stimulant ingredients, or proprietary formulations.

Effective quality-control programs should include appropriate raw-material identification, supplier qualification, finished-product testing, and manufacturing documentation.

The objective is not merely to confirm that a product contains its declared ingredients but also to detect potentially hazardous or unlawful substances that may be present through adulteration, contamination, or formulation practices.

The publicly available recall announcement establishes that FDA testing detected DMAA in RAPTURE Preworkout. However, it does not disclose the measured DMAA concentration, the specific analytical method used, or the circumstances responsible for its presence.

Therefore, conclusions regarding the precise dose delivered per serving or the source of the compound would be speculative.

RAPTURE Preworkout Recall Details

The affected products were distributed in 450-gram plastic containers featuring red-and-black lettering and a rhinoceros-print seal.

All three affected varieties are associated with lot number 260327-4.

Consumers possessing products from this lot have been instructed to discontinue use and return them to the place of purchase for a full refund.

Individuals who experience potentially supplement-related health problems should seek appropriate medical evaluation. Serious suspected adverse reactions may also be reported through the FDA’s MedWatch program.

Broader Implications for the Sports Nutrition Industry

The continued detection of DMAA in commercial supplements illustrates a recurring challenge within the performance nutrition marketplace: balancing consumer demand for noticeable stimulant effects with scientific evidence, toxicological safety, and regulatory compliance.

Pre-workout formulations are frequently marketed around immediate subjective effects, including increased energy, heightened concentration, and intensified exercise sensations.

However, these experiences do not necessarily correlate with improved athletic outcomes, nor do they establish that a formulation is safe for repeated consumption.

For manufacturers, the RAPTURE recall emphasizes the importance of transparent ingredient declarations, validated analytical procedures, and compliance with federal dietary supplement regulations.

For consumers, it reinforces the need to distinguish between products supported by controlled human research and formulations relying primarily on stimulant intensity as a measure of effectiveness.

Conclusion

The nationwide recall of RAPTURE Preworkout following FDA detection of DMAA represents another chapter in the longstanding controversy surrounding stimulant-containing dietary supplements.

DMAA possesses pharmacological properties capable of producing significant physiological stimulation, particularly involving cardiovascular regulation. However, its incomplete clinical safety characterization, potential cardiovascular risks, and unlawful regulatory status in dietary supplements remain substantial concerns.

Although the manufacturer reported no associated adverse events at the time of the recall, that finding does not establish the safety of the affected products or DMAA itself.

Ultimately, the scientific evaluation of performance-enhancing supplements must extend beyond immediate subjective effects to include controlled efficacy data, toxicological assessment, ingredient authenticity, and regulatory compliance.

A stimulant’s ability to produce noticeable physiological effects should never be mistaken for scientific evidence of safety or superior athletic performance.

Scientific and Regulatory References